Center for High Performance Computing, Joint Engineering Research Center for Health Big Data Intelligent Analysis Technology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, People's Republic of China.
Shenzhen Key Laboratory of Pathogen and Immunity, Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, State Key Discipline of Infectious Disease, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen Third People's Hospital, Shenzhen, 518112, People's Republic of China.
Interdiscip Sci. 2020 Sep;12(3):368-376. doi: 10.1007/s12539-020-00376-6. Epub 2020 Jun 1.
A novel coronavirus, called 2019-nCoV, was recently found in Wuhan, Hubei Province of China, and now is spreading across China and other parts of the world. Although there are some drugs to treat 2019-nCoV, there is no proper scientific evidence about its activity on the virus. It is of high significance to develop a drug that can combat the virus effectively to save valuable human lives. It usually takes a much longer time to develop a drug using traditional methods. For 2019-nCoV, it is now better to rely on some alternative methods such as deep learning to develop drugs that can combat such a disease effectively since 2019-nCoV is highly homologous to SARS-CoV. In the present work, we first collected virus RNA sequences of 18 patients reported to have 2019-nCoV from the public domain database, translated the RNA into protein sequences, and performed multiple sequence alignment. After a careful literature survey and sequence analysis, 3C-like protease is considered to be a major therapeutic target and we built a protein 3D model of 3C-like protease using homology modeling. Relying on the structural model, we used a pipeline to perform large scale virtual screening by using a deep learning based method to accurately rank/identify protein-ligand interacting pairs developed recently in our group. Our model identified potential drugs for 2019-nCoV 3C-like protease by performing drug screening against four chemical compound databases (Chimdiv, Targetmol-Approved_Drug_Library, Targetmol-Natural_Compound_Library, and Targetmol-Bioactive_Compound_Library) and a database of tripeptides. Through this paper, we provided the list of possible chemical ligands (Meglumine, Vidarabine, Adenosine, D-Sorbitol, D-Mannitol, Sodium_gluconate, Ganciclovir and Chlorobutanol) and peptide drugs (combination of isoleucine, lysine and proline) from the databases to guide the experimental scientists and validate the molecules which can combat the virus in a shorter time.
一种新型冠状病毒,称为 2019-nCoV,最近在中国湖北省武汉市被发现,目前正在中国和世界其他地区传播。虽然有一些药物可以治疗 2019-nCoV,但关于其对病毒的活性还没有适当的科学证据。开发一种能够有效对抗病毒的药物来拯救宝贵的生命具有重要意义。使用传统方法开发药物通常需要更长的时间。对于 2019-nCoV,现在最好依靠深度学习等替代方法来开发能够有效对抗此类疾病的药物,因为 2019-nCoV 与 SARS-CoV 高度同源。在本工作中,我们首先从公共数据库中收集了 18 例报道的 2019-nCoV 患者的病毒 RNA 序列,将 RNA 翻译为蛋白质序列,并进行了多序列比对。经过仔细的文献调查和序列分析,认为 3C 样蛋白酶是主要的治疗靶点,我们使用同源建模构建了 3C 样蛋白酶的蛋白质 3D 模型。依靠结构模型,我们使用基于深度学习的方法,通过大规模虚拟筛选,准确地对我们小组最近开发的蛋白质-配体相互作用对进行排名/识别。我们的模型通过对四个化学化合物数据库(Chimdiv、Targetmol-Approved_Drug_Library、Targetmol-Natural_Compound_Library 和 Targetmol-Bioactive_Compound_Library)和三肽数据库进行药物筛选,鉴定出了针对 2019-nCoV 3C 样蛋白酶的潜在药物。通过本文,我们提供了可能的化学配体(葡甲胺、阿昔洛韦、腺苷、山梨醇、甘露醇、葡萄糖酸钠、更昔洛韦和氯丁醇)和肽类药物(异亮氨酸、赖氨酸和脯氨酸组合)的列表,来自数据库的指导实验科学家并验证可以在更短的时间内对抗病毒的分子。